{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:52:49Z","timestamp":1791899569173,"version":"4.3.4"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T00:00:00Z","timestamp":1225324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Relapsed or refractory mantle cell lymphoma has a very poor prognosis. The authors evaluated the response rates and survival times of patients treated with an intense regimen known to be effective against untreated aggressive mantle cell lymphoma: rituximab plus hyper\u2010CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) alternating with rituximab plus methotrexate\u2010cytarabine.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>In this prospective, open\u2010label, phase 2 study, patients received this combination for 6 to 8 cycles. Twenty\u2010nine patients were evaluable for response.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>The median number of cycles received was 5 (range, 1\u20107 cycles), and the overall response rate was 93% (45% complete response [CR] or CR unconfirmed [CRu] and 48% partial response [PR]). All 5 patients previously resistant to treatment had a response (1 CR, 4 PR), and both patients whose disease did not change in response to prior therapy had PRs. Toxic events occurring in response to the 104 cycles given included neutropenic fever (11%), grade 3 or 4 neutropenia (74%), and grade 3 or 4 thrombocytopenia (63%). There were no deaths from toxicity. At a median follow\u2010up of 40 months (range, 5\u201048 months), the median failure\u2010free survival time was 11 months with no plateau in the survival curve.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>This combination chemotherapy was effective for refractory\/relapsed mantle cell lymphoma. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23880","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T09:27:56Z","timestamp":1225358876000},"page":"2734-2741","source":"Crossref","is-referenced-by-count":32,"title":["Phase 2 trial of rituximab plus hyper\u2010CVAD alternating with rituximab plus methotrexate\u2010cytarabine for relapsed or refractory aggressive mantle cell lymphoma"],"prefix":"10.1002","volume":"113","author":[{"given":"Michael","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070505"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059154"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2067"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of 2 indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including mucosa\u2010associated lymphoid tissue and monocytoid B\u2010cell categories). a Southwest Oncology Group study","volume":"85","author":"Fisher RI","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.501"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_6_12_2","first-page":"25","article-title":"Prognostic factors for survival in patients with inoperative lung cancer","volume":"65","author":"Stanley KE","year":"1980","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2000.00895.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/112.4.524"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1309\/69EJ-RFM5-E976-BUTP"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.2307\/2344317"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008278522789"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1091"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.071"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097721"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012551809100"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"issue":"1","key":"e_1_2_6_30_2","first-page":"361A","article-title":"Fludarabine, mitoxantrone, and rituxan: an effective regimen for the treatment of mantle cell lymphoma","volume":"100","author":"Levine AM","year":"2002","journal-title":"Blood"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22196"},{"issue":"18","key":"e_1_2_6_34_2","first-page":"450S","article-title":"R\u2010Dhaox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed or refractory (R\/R) follicular (F) and mantle cell (MC) lymphomas (NHL)","volume":"100","author":"Rupolo M","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"779A","DOI":"10.1182\/blood.V108.11.2753.2753","article-title":"Marked activity of bortezomib, rituximab and dexamethasone in relapsed and refractory mantle cell lymphoma","volume":"108","author":"Drach J","year":"2006","journal-title":"Blood"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23880","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:31:24Z","timestamp":1760275884000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,3]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,11,15]]}},"alternative-id":["10.1002\/cncr.23880"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23880","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,3]]}}}